𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A strategic framework for novel drug development in multiple myeloma

✍ Scribed by Kenneth C. Anderson; Alison L. Hannah; Richard Pazdur; Ann T. Farrell

Book ID
108675270
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
650 KB
Volume
138
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Future drug developments in multiple mye
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
✍ Gareth Morgan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 214 KB

The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes. These novel agents are often used in combination with conventional drugs, such as dexamethasone, to optimize clinical responses; however

Development of a novel biocompatible pol
Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent
✍ Kishore Udipi; Mingfei Chen; Peiwen Cheng; Kevin Jiang; Diane Judd; Alejandra Ca 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 2 views

## Abstract Drug‐eluting stents have proven superior to bare metal stents with lower restenosis rates. Local delivery of drugs from these stents is achieved in most cases with the help of biostable polymer coatings. However, since the polymer coating remains in the body well after all the drug is r

Tartrate-resistant acid phosphatase isof
Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma
✍ Evangelos Terpos; Josu de la Fuente; Richard Szydlo; Evdoxia Hatjiharissi; Nora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 80 KB

## Abstract Tartrate‐resistant acid phosphatase isoform‐5b (TRACP‐5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with

Duplication of chromosome arms 9q and 11
Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocation–independent pathogenetic pathway in multiple myeloma
✍ Peter Liebisch; Daniel Scheck; Seiichi Alvise Erné; Alexander Wellmann; Christia 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

## Abstract 14q32 translocations [t(14q)] represent critical but not universal events in multiple myeloma (MM). Gains of chromosome arms 1q, 9q, and 11q (+1q, +9q, and +11q) have recently been identified as frequent aberrations in this disease, but their pathogenetic significance remains unclear. W

Novel evidence of a role for chromosome
Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma
✍ Patricia Le Baccon; Dominique Leroux; Christina Dascalescu; Samuel Duley; Daniel 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 322 KB

## Abstract 1q rearrangement is a remarkably frequent secondary chromosomal change in both non‐Hodgkin's lymphoma (NHL) and multiple myeloma (MM), where it is associated with tumor progression. To gain insight into 1q rearrangement‐associated disease mechanisms, we used fluorescence in situ hybridi